The trial judge's gatekeeping role is to ensure reliability rather than to weigh the strength of the evidence, as the level of expertise goes to the weight of testimony.
Plaintiffs sued a pest control company for injuries allegedly caused by pesticide exposure. The district court excluded the plaintiffs' medical expert's opinion on causation, finding it lacked a sufficient factual foundation, and granted summary judgment for the defendant. On appeal, the court addressed whether the expert's testimony was properly excluded. Applying the Federal Rules of Evidence, the court held that the trial judge's gatekeeping role is to ensure reliability, not to weigh the strength of the evidence. Because the expert's opinion was based on medical records, neuropsychological reports, and application receipts, the court concluded the testimony met the requirements for admissibility. The level of an expert's expertise goes to the weight of the evidence, not its admissibility.
At page 806 Distinguishing admissibility from credibility determinations173 citing cases“neither exhaustive nor applicable in every case.”
- Nat'l Prods. Inc v. Innovative Intelligent Prods. LLC, No. 2:20-cv-00428 (W.D. Wash. July 30, 2024).(Daubert does not set 14 up a test of which opinion has the best foundation, but rather whether any particular opinion is 15 based on valid reasoning and reliable methodology.)
- United States v. Roberts, No. 3:20-cv-00010 (D.V.I. Sept. 14, 2023). Not only are trial courts given broad discretion during the expert qualification analysis, but judges are also encouraged to construe the term qualified witness “liberally” given the Rules of Evidence’s “strong preference for admitting any…
- Mihalick v. Delvaux, 589 F. Supp. 3d 497 (W.D. Pa. 2022).published See United States v. Mitchell, 365 F.3d 215, 244 (3d Cir. 2004) (Daubert demands only that the proponent of the evidence show that the expert's conclusion has been arrived at in a scientifically sound and methodologically reliable manner)…
- Williams v. Benshetrit, No. 2:19-cv-00797 (E.D. Pa. Dec. 17, 2021).(Rule 702 . . . has a liberal policy of admissibility.)
- Graham Eng'g Corp. v. Slusarz, No. 1:16-cv-02527 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Graham Eng'g Corp. v. Kramer, No. 1:16-cv-02523 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Graham Eng'g Corp. v. Adair, No. 1:16-cv-02521 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Graham Eng'g Corp. v. Lawton, No. 1:16-cv-02524 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Graham Eng'g Corp. v. Perri, No. 1:16-cv-02525 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Graham Eng'g Corp. v. Johnson, No. 1:16-cv-02522 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
Show 158 more citing cases
- Graham Enginerring Corp. v. Schilke, No. 1:16-cv-02526 (M.D. Pa. Mar. 15, 2021). (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- K.R.Y.S. v. Aaron, 112 F. Supp. 3d 181 (D.N.J. 2015).published See Kannankeril, 128 F.3d at 809 (“If [an] expert meets [the] liberal minimum qualifications, then the level of [an] expert’s expertise goes to credibility and weight, not admissibility.”).
- Pritchard v. Dow Agro Sciences, 705 F. Supp. 2d 471 (W.D. Pa. 2010).published Co., 80 F.3d 777, 782 (3d Cir.1996)); see also Kannankeril, 128 F.3d at 809 (“We reject [defendant’s] suggestion that [the doctor] must be an expert in Dursban to provide expert testimony on the causation of [plaintiffs] injury.”).
- Pineda v. Ford Motor Co., 520 F.3d 237 (3d Cir. 2008).published (Admissibility decisions focus on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.)
- Traharne v. Wayne/Scott Fetzer Co., 156 F. Supp. 2d 697 (N.D. Ill. 2001).published Kannankeril v. Terminix International, Inc., 128 F.3d 802 , 809 (3d Cir.1997). 87 .
- Perciballi, No. 2:23-cv-00948 (D.N.J. Jan. 29, 2026).unpublished However, “the test of admissibility is not whether a particular scientific opinion has the best foundation . . . [r]ather, the test is whether the ‘particular opinion is based on valid reasoning and reliable methodology.’” In re TMI Litig.…
- Young v. Chipotle Mexican Grill of Colorado, LLC, No. 2:22-cv-07452 (D.N.J. June 26, 2025).unpublishedLEGAL STANDARD A. Motion to Exclude Expert Testimony Under the Federal Rules of Evidence, it is the trial judge’s job “to act as a ‘gatekeeper’ to ensure that any and all expert testimony or evidence is not only relevant, but also reliable…
- Young v. Jabil, Inc., No. 2:23-cv-04992 (E.D. Pa. May 19, 2025).Rule 702 “has a liberal policy of admissibility.” Pineda v. Ford Motor Co., 520 F.3d 237, 243 (3d Cir. 2008) (quoting Kannankeril v. Terminix Int’l, Inc., 128 F.3d 802, 806 (3d Cir. 1997)).
- Oterra A/S v. Wild Flavors, Inc., No. 1:23-cv-01376 (D. Del. May 16, 2025).Admissibility turns “on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.” Kannankeril v. Terminix Intern., Inc., 128 F.3d 802, 806 (3d Cir. 1997).
- Riya Dev Corp. v. Amguard Ins. Co., No. 1:22-cv-06415 (D.N.J. Mar. 25, 2025).“Under the Federal Rules of Evidence, it is the role of the trial judge to act as a ‘gatekeeper’ to ensure that any and all expert testimony or evidence is not only relevant, but also reliable.” Kannankeril v. Terminix Int’l, Inc., 128 F.3…
- Lorenzo-noda v. Kazak, No. 2:18-cv-13414 (D.N.J. Mar. 24, 2025).unpublishedKannankeril v. Terminix Int’l, Inc., 128 F.3d 802, 806 (3d Cir. 1997).
- Milan v. New Jersey Transit Rail Operations, Inc., No. 2:18-cv-13735 (D.N.J. Mar. 18, 2025).“Under the Federal Rules of Evidence, it is the role of the trial judge to act as a ‘gatekeeper’ to ensure that any and all expert testimony or evidence is not only relevant, but also reliable.” Kannankeril v. Terminix Int’l, Inc., 128 F.3…
- 10X Genomics, Inc. v. Parse Biosciences, Inc., No. 1:22-cv-01117 (D. Del. Feb. 21, 2025). Admissibility turns “on the expert’s methods and reasoning; credibility decisions arise after admissibility has been determined.” Kannankeril v. Terminix Intern., Inc., 128 F.3d 802, 806 (3d Cir. 1997).
- Boncher v. 3M Co., No. 5:24-cv-01403 (E.D. Pa. Feb. 14, 2025). Pa. Apr. 18, 2024) (citing Kannankeril v. Terminix Int'l, Inc., 128 F.3d 802, 806 (3d Cir. 1997), as amended (Dec. 12, 1997)).
- United States v. JOHNSON & JOHNSON, No. 3:12-cv-07758 (D.N.J. Jan. 30, 2025).unpublishedRule 702 “has a liberal policy of admissibility.” Kannankeril v. Terminix Int’l, Inc., 128 F.3d 802, 806 (3d Cir. 1997) (citation omitted).
- PNC Fin. Servs. Grp., Inc. v. Plaid Inc., No. 2:20-cv-01977 (W.D. Pa. Aug. 7, 2024).Though the FRE “embody a strong preference for admitting any evidence that may assist the trier of fact,” and “Rule 702 . . . has a liberal policy of admissibility,” Pineda v. Ford Motor Co., 520 F.3d 237, 243 (3d Cir. 2008) (quoting Kanna…
- Brooks v. Trans Union LLC, 743 F. Supp. 3d 622 (E.D. Pa. 2024).Rule 702 requires the trial judge to act as a “gatekeeper,” ensuring that “any and all expert testimony or evidence is not only relevant, but also reliable.” Pineda v. Ford Motor Co., 520 F.3d 237, 243 (3d Cir. 2008) (quoting Kannankeril v…
- Harbor Bus. Compliance Corp. v. Firstbase.io, Inc., No. 5:23-cv-00802 (E.D. Pa. Apr. 3, 2024).LEGAL STANDARD A. Expert Testimony – Review of Applicable Law “Under the Federal Rules of Evidence, it is the role of the trial judge to act as a ‘gatekeeper’ to ensure that any and all expert testimony or evidence is not only relevant, bu…
- Brand Design Co. v. Rite Aid Corp., No. 2:22-cv-01174, 2024 WL 643141 (E.D. Pa. Feb. 14, 2024).But those disagreements just go to the correctness of Rogers’ opinions, a question “for the trier of fact when the expert is subjected to cross-examination.” Oddi, 234 F.3d at 146 (quoting Kannankeril v. Terminix Int’l Inc., 128 F.3d 802,…
- Wirtgen Am., Inc. v. Caterpillar, Inc., 715 F. Supp. 3d 587 (D. Del. 2024).Rule 702 “has a liberal policy of admissibility.” at 243 (quoting , 128 F.3d 802, 806 (3d Cir. 1997)). .
- In re TMI Litig., 193 F.3d 613 (3d Cir. 1999).
- Dodge v. Cotter Corp., 203 F.3d 1190 (10th Cir. 2000).published
- Ruiz-Troche v. Pepsi Cola of Puerto Rico Bottling Co., 161 F.3d 77 (1st Cir. 1998).published
- In re Tmi Litig. Lori Dolan Joseph Gaughan Ronald Ward Est. of Pearl Hickernell Kenneth Putt Est. of Ethelda Hilt Paula Obercash Jolene Peterson Est. of Gary Villella Est. of Leo Beam, No. 96-7623 in Re: Tmi Litig. All Except Lori Dolan, Joseph Gaughan, Ronald Ward, Est. of Pearl Hickernell, Kenneth Putt, Est. of Ethelda Hilt, Paula Obercash, Jolene Peterson, Est. of Gary Villella & Est. of Leo Beam, No. 96-7624 in Re: Tmi Litig., 193 F.3d 613 (3d Cir. 1999).published
- David Oddi v. Ford Motor Co., 234 F.3d 136 (3d Cir. 2000).published
- United States v. Byron Mitchell, 365 F.3d 215 (3d Cir. 2004).published
- San Francisco v. Wendy's Int'l, Inc., 656 S.E.2d 485 (W. Va. 2007).published
- In re Flood Litig. Coal River Watershed, 668 S.E.2d 203 (W. Va. 2008).published
- Bowers v. Nat'l Collegiate Athletic Ass'n, 564 F. Supp. 2d 322 (D.N.J. 2008).published
- Bauer v. Bayer A.G., 564 F. Supp. 2d 365 (M.D. Pa. 2008).published
- Sec. & Exch. Comm'n v. Lucent Tech., Inc., 610 F. Supp. 2d 342 (D.N.J. 2009).published
- Viking Yacht Co. v. Composites One LLC, 615 F. Supp. 2d 327 (D.N.J. 2009).published
- In re Young Broad. Inc., 430 B.R. 99 (Bankr. S.D.N.Y. 2010).published
- Brill v. Marandola, 540 F. Supp. 2d 563 (E.D. Pa. 2008).published
- DiPetrillo v. Dow Chem. Co., 729 A.2d 677 (R.I. 1999).published
- Minner v. Am. Mortg. & Guar. Co., 791 A.2d 826 (Del. Super. Ct. 2000).published
- Keller v. Feasterville Fam. Health Care Ctr., 557 F. Supp. 2d 671 (E.D. Pa. 2008).published
- Hamilton v. Emerson Elec. Co., 133 F. Supp. 2d 360 (M.D. Pa. 2001).published
- Hoang v. Funai Corp., 652 F. Supp. 2d 564 (M.D. Pa. 2009).published
- Traharne v. Wayne Scott Fetzer Co., 156 F. Supp. 2d 717 (N.D. Ill. 2001).published
- Martinez v. Triad Controls, Inc., 593 F. Supp. 2d 741 (E.D. Pa. 2009).published
- United States v. Trala, 162 F. Supp. 2d 336 (D. Del. 2001).published
- Viking Yacht Co. v. Composites One LLC, 613 F. Supp. 2d 637 (D.N.J. 2009).published
- Animal Sci. Prods., Inc. v. China Nat'l Metals & Minerals Imp. & Exp. Corp., 702 F. Supp. 2d 320 (D.N.J. 2010).published
- FedEx Ground Package Sys., Inc. v. Applications Int'l Corp., 695 F. Supp. 2d 216 (W.D. Pa. 2010).published
- McAndrew v. Garlock Equip. Co., 537 F. Supp. 2d 731 (M.D. Pa. 2008).published
- Arlington Indus., Inc. v. Bridgeport Fittings, Inc., 658 F. Supp. 2d 630 (M.D. Pa. 2009).published
- Buzzerd v. Flagship Carwash of Port St. Lucie, Inc., 669 F. Supp. 2d 514 (M.D. Pa. 2009).published
- Ebenhoech v. Koppers Indus., Inc., 239 F. Supp. 2d 455 (D.N.J. 2002).published
- Main Street Mortg., Inc. v. Main Street Bancorp, Inc., 158 F. Supp. 2d 510 (E.D. Pa. 2001).published
- McCoy v. Whirlpool Corp., 379 F. Supp. 2d 1187 (D. Kan. 2005).published
- United States v. West Indies Transp. Co., 57 F. Supp. 2d 198 (D.V.I. 1999).published
- Fireman's Fund Ins. v. Xerox Corp., 30 F. Supp. 2d 823 (M.D. Pa. 1998).published
- Eclipse Elec. v. Chubb Corp., 176 F. Supp. 2d 406 (E.D. Pa. 2001).published
- Magistrini v. One Hour Martinizing Dry Cleaning, 180 F. Supp. 2d 584 (D.N.J. 2002).published
- Ellison v. United States, 753 F. Supp. 2d 468 (E.D. Pa. 2010).published
- Rapp v. Singh, 152 F. Supp. 2d 694 (E.D. Pa. 2001).published
- Ruff v. Ensign-bickford Indus., Inc., 171 F. Supp. 2d 1226 (D. Utah 2001).published
- ProtoComm Corp. v. Novell Advanced Servs., Inc., 171 F. Supp. 2d 473 (E.D. Pa. 2001).published
- David v. Black & Decker (US) Inc., 629 F. Supp. 2d 511 (W.D. Pa. 2009).published
- Est. of Creek v. Mittal Steel USA, Inc., 629 F. Supp. 2d 502 (W.D. Pa. 2008).published
- Holman Enter. v. Fid. & Guar. Ins., 563 F. Supp. 2d 467 (D.N.J. 2008).published
- ID Sec. Sys. Canada, Inc. v. Checkpoint Sys., Inc., 198 F. Supp. 2d 598 (E.D. Pa. 2002).published
- United States v. Prime, 220 F. Supp. 2d 1203 (W.D. Wash. 2002).published
- Fisher v. Walsh Parts & Serv. Co., 277 F. Supp. 2d 496 (E.D. Pa. 2003).published
- Dearson v. Bostrom Seating, Inc., 241 F. Supp. 2d 494 (E.D. Pa. 2003).published
- Consulnet Computing, Inc. v. Moore, 631 F. Supp. 2d 614 (E.D. Pa. 2008).published
- United States v. Scripps, 599 F. App'x 443 (3d Cir. 2015).unpublished
- United States v. Mitchell, No. 02-2859 (3d Cir. Apr. 29, 2004).published
- Player v. Motiva Enters., LLC, 240 F. App'x 513 (3d Cir. 2007).unpublished
- Marcavage v. Bd Trs. Temple, 232 F. App'x 79 (3d Cir. 2007).unpublished
- United States v. Staples, 266 F. App'x 167 (3d Cir. 2008).unpublished
- State of West Virginia v. Richard Wakefield, 781 S.E.2d 222 (W. Va. 2015).published
- In re SemCrude L.P., 648 F. App'x 205 (3d Cir. 2016).unpublished
- United States ex rel. Customs Fraud Investigations, LLC v. Victaulic Co., 839 F.3d 242 (3d Cir. 2016).published
- United States v. Raymont Wright, 913 F.3d 364 (3d Cir. 2019).published
- United States v. Yunior Fernandez, 795 F. App'x 153 (3d Cir. 2020).unpublished
- Seneca Ins. Co v. Mark Beal, 820 F. App'x 106 (3d Cir. 2020).unpublished
- Fillebrown v. Steelcase, Inc., 63 F. App'x 54 (3d Cir. 2003).unpublished
- Hartle v. FirstEnergy Generation Corp., 7 F. Supp. 3d 510 (W.D. Pa. 2014).published
- Rowland v. Novartis Pharm. Corp., 9 F. Supp. 3d 553 (W.D. Pa. 2014).published
- Kemly v. Werner Co., 151 F. Supp. 3d 496 (D.N.J. 2015).published
- In re Urethane Antitrust Litig., 152 F. Supp. 3d 357 (D.N.J. 2016).published
- In re Urethane Antitrust Litig., 166 F. Supp. 3d 501 (D.N.J. 2016).published
- Smart Vent, Inc. v. USA Floodair Vents, Ltd., 193 F. Supp. 3d 395 (D.N.J. 2016).published
- Terry v. McNeil-PPC, Inc., 198 F. Supp. 3d 446 (E.D. Pa. 2016).published
- Dorman Prods., Inc. v. Paccar, Inc., 201 F. Supp. 3d 663 (E.D. Pa. 2016).published
- Comcast Cable Commc'ns, LLC v. Sprint Commc'ns Co., 218 F. Supp. 3d 375 (E.D. Pa. 2016).published
- Reckitt Benckiser LLC v. Aurobindo Pharma Ltd., 239 F. Supp. 3d 822 (D. Del. 2017).published
- Gov't of the Virgin Islands v. Greenidge, 41 V.I. 200 (D.V.I. 1998).published
- Sterling v. Redevelopment Auth., 836 F. Supp. 2d 251 (E.D. Pa. 2011).published
- Furlan v. Schindler Elevator Corp., 864 F. Supp. 2d 291 (E.D. Pa. 2012).published
- Wolfe v. McNeil-PPC, Inc., 881 F. Supp. 2d 650 (E.D. Pa. 2012).published
- In re Flonase Antitrust Litig., 907 F. Supp. 2d 637 (E.D. Pa. 2012).published
- Buddy's Plant Plus Corp. v. Centimark Corp., 978 F. Supp. 2d 523 (W.D. Pa. 2013).published
- In re Hydrogen Peroxide Antitrust Litig., 240 F.R.D. 163 (E.D. Pa. 2007).published
- Merisant Co. v. McNeil Nutritionals, LLC, 242 F.R.D. 315 (E.D. Pa. 2007).published
- Madden v. A.I. Dupont Hosp. for Child. of Nemours Found., 264 F.R.D. 209 (E.D. Pa. 2010).published
- In re Chocolate Confectionary Antitrust Litig., 289 F.R.D. 200 (M.D. Pa. 2012).published
- Lithuanian Com. Corp. v. Sara Lee Hosiery, 177 F.R.D. 245 (D.N.J. 1997).published
- TQ Delta LLC v. 2Wire Inc., No. 1:13-cv-01835 (D. Del. June 30, 2021).
- Harder v. Union Pac. R.R. Co., No. 8:18-cv-00058 (D. Neb. Jan. 29, 2020).
- B.Y.R.D. v. Union Pac. R.R. Co., 453 F. Supp. 3d 1260 (D. Neb. 2020).published
- West v. Union Pac. R.R. Co., No. 8:17-cv-00036 (D. Neb. Feb. 3, 2020).
- Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., No. 3:17-cv-05319 (D.N.J. June 15, 2020).unpublished
- Callas v. Callas, No. 2:14-cv-07486 (D.N.J. June 25, 2020).unpublished
- Mestre v. Garden Homes Mgmt. Corp., No. 1:16-cv-03231 (D.N.J. July 13, 2020).
- Healthquest of Cent. Jersey, LLC v. Antares Aul Syndicate 1274, No. 3:18-cv-12375, 2020 WL 4431770 (D.N.J. July 31, 2020).unpublished
- Florio v. Ryobi Tech., Inc., No. 1:17-cv-05518 (D.N.J. Sept. 2, 2020).
- Christoforetti v. Bally's Park Place, Inc., No. 1:12-cv-04687, 2021 WL 3879074 (D.N.J. Aug. 31, 2021).
- Sakolsky v. Genie Indus., No. 2:15-cv-06893 (D.N.J. Aug. 18, 2021).unpublished
- Lewis v. Gov't Employees Ins. Co., No. 1:18-cv-05111, 2022 WL 819611 (D.N.J. Mar. 18, 2022).
- Faragalla v. Jersey City, No. 2:17-cv-03604 (D.N.J. Sept. 7, 2022).
- Jason v. Nat'l R.R. Passenger Corp., No. 2:17-cv-07873 (D.N.J. Oct. 28, 2022).unpublished
- Tramontano v. New Jersey Transit Rail Operations, Inc., No. 2:14-cv-05706 (D.N.J. May 4, 2023).unpublished
- Equinox Props., LLC v. Harford Mut. Ins. Co., No. 1:21-cv-15929, 2023 WL 5447279 (D.N.J. Aug. 24, 2023).
- Failla v. George's Foods, LLC, No. 2:20-cv-07109, 2023 WL 7298473 (D.N.J. Nov. 6, 2023).unpublished
- Blue Cross Blue Shield Ass'n v. Glaxosmithkline LLC, 417 F. Supp. 3d 531 (E.D. Pa. 2019).published
- Jacoby Donner, P.C. v. Aristone Realty Capital, LLC, No. 2:17-cv-02206 (E.D. Pa. Aug. 28, 2020).
- Wichterman v. City of Philadelphia, No. 2:16-cv-05796 (E.D. Pa. Dec. 21, 2020).
- Kenney v. Watts Regulator Co., 512 F. Supp. 3d 565 (E.D. Pa. 2021).published
- Winn-dixie Stores, Inc. v. E. Mushroom Mktg. Coop., Inc., No. 5:15-cv-06480 (E.D. Pa. June 9, 2021).
- T.N. Incorporation Ltd. v. Fid. Nat'l Info. Servs., Inc., No. 2:18-cv-05552, 2021 WL 5980048 (E.D. Pa. Dec. 17, 2021).
- Didonato v. Stanley Black & Decker, No. 2:20-cv-04425 (E.D. Pa. Feb. 9, 2022).
- Durando v. Trs. of the Univ. of Pennsylvania, No. 2:21-cv-00756 (E.D. Pa. July 6, 2022).
- Arcuri v. Cnty. of Montgomery, No. 2:20-cv-05408 (E.D. Pa. Aug. 16, 2022).
- Torain v. City of Philadelphia, No. 2:14-cv-01643 (E.D. Pa. Jan. 12, 2023).
- Value Drug Co. v. Takeda Pharm., U.s.a., Inc., No. 2:21-cv-03500 (E.D. Pa. Feb. 28, 2023).
- Benton v. CSX Transp., Inc., No. 2:19-cv-00109 (E.D. Pa. June 16, 2023).
- F.E.I. Co. v. United States, No. 1:16-cv-02237 (M.D. Pa. Aug. 12, 2019).
- \R.D\" v. Shohola Camp Ground & Resort", No. 3:16-cv-01056 (M.D. Pa. Aug. 13, 2019).
- State Farm Fire & Cas. Co. v. IDC Mgmt. Co., No. 3:18-cv-01282 (M.D. Pa. Oct. 25, 2019).
- Shelton v. Gure, No. 3:19-cv-00843, 2021 WL 2210989 (M.D. Pa. June 1, 2021).
- Santiago v. Walmart Stores, Inc., No. 1:17-cv-00166 (W.D. Pa. Oct. 11, 2019).
- Fed. Trade Comm'n v. Innovative Designs, Inc., No. 2:16-cv-01669, 2020 WL 758727 (W.D. Pa. Feb. 14, 2020).
- Mcbride v. Petulla, No. 3:16-cv-00256, 2020 WL 1032535 (W.D. Pa. Mar. 3, 2020).
- Lopez v. CSX Transp., Inc., No. 3:14-cv-00257 (W.D. Pa. July 6, 2021).
- Repa v. Napierkowski, No. 1:19-cv-00101 (W.D. Pa. May 5, 2022).
- Repa v. Napierkowski, No. 1:19-cv-00101 (W.D. Pa. May 13, 2022).
- Wilkoski v. B&T Express, Inc, No. 2:18-cv-01359 (W.D. Pa. Sept. 19, 2022).
- Borghese Lane, LLC, No. 2:18-cv-00533 (W.D. Pa. Mar. 2, 2023).
- Power v. Hewlett-packard Co., No. 2:17-cv-00154 (W.D. Pa. Mar. 30, 2023).
- Grasinger v. Caterpillar Inc., No. 2:21-cv-00956, 2023 WL 4846843 (W.D. Pa. July 28, 2023).
- Great Lakes Ins. S.E. v. Sunshine Shopping Ctr., Inc., No. 1:19-cv-00039 (D.V.I. Sept. 30, 2022).
- Certain Underwriters at Lloyd's v. Sunshine Shopping Ctr., Inc., No. 1:20-cv-00033 (D.V.I. Sept. 30, 2022).
- Rogers v. Blair, No. 2:24-cv-01534 (E.D. Pa. July 28, 2025).
- Poust v. Huntleigh Healthcare, 998 F. Supp. 478 (D.N.J. 1998).published
- Veloso v. W. Bedding Supply Co., 281 F. Supp. 2d 743 (D.N.J. 2003).published
- Dalton v. McCourt Elec. LLC, 112 F. Supp. 3d 320 (E.D. Pa. 2015).published
- Dandy v. Ethicon Women's Health & Urology, 579 F. Supp. 3d 625 (D.N.J. 2022).
- Smith v. State Farm Fire & Cas. Co., No. 1:19-cv-10319 (D.N.J. May 19, 2023).
- Bradley v. Easyacc.com, Inc., No. 2:17-cv-01587 (E.D. Pa. Mar. 17, 2023).
- Gorton v. Air & Liquid Sys. Corp., No. 1:17-cv-01110 (M.D. Pa. July 21, 2020).
- Whalley v. Blazick, No. 4:18-cv-01295-MCC (M.D. Pa. Aug. 3, 2021).
- Michaux v. Temas, No. 2:17-cv-01241 (W.D. Pa. Dec. 5, 2019).
- Qasim, No. 2:21-cv-18744 (D.N.J. Jan. 12, 2026).
- Jellison, No. 2:23-cv-00739 (W.D. Pa. Jan. 20, 2026).
- Alexander, No. 2:21-cv-15002 (D.N.J. Jan. 14, 2026).unpublished
At page 809 Distinguishing expert qualifications from testimony weight67 citing cases“if the expert meets liberal minimum qualifications, then the level of the expert's expertise goes to credibility and weight, not admissibility.”
- United States v. Roberts, No. 3:20-cv-00010 (D.V.I. Sept. 14, 2023). (If the expert meets liberal minimum qualifications, then the level of the expert's expertise goes to credibility and weight, not admissibility.)
- Mihalick v. Delvaux, 589 F. Supp. 3d 497 (W.D. Pa. 2022).published (The trial judge must be careful not to mistake credibility questions for admissibility questions.)
- K.R.Y.S. v. Aaron, 112 F. Supp. 3d 181 (D.N.J. 2015).published (If [an] expert meets [the] liberal minimum qualifications, then the level of [an] expert’s expertise goes to credibility and weight, not admissibility.)
- Pritchard v. Dow Agro Sciences, 705 F. Supp. 2d 471 (W.D. Pa. 2010).published (We reject [defendant’s] suggestion that [the doctor] must be an expert in Dursban to provide expert testimony on the causation of [plaintiffs] injury.)
- Floorgraphics, Inc. v. News Am. Mktg. In-Store Servs., Inc., 546 F. Supp. 2d 155 (D.N.J. 2008).published (we reject Terminix’s suggestion that Dr. Gerson must be a specialist in Dursban to provide expert testimony on the causation of [Plaintiffs] injury)
- In re Unisys, No. 98-1007 (3d Cir. Mar. 22, 1999). (If the expert meets liberal minimum qualifications [under Rule 702], then the level of the expert's expertise goes to credibility and weight, not admissibility.)
- Meinhardt v. Unisys Corp., 173 F.3d 145 (3d Cir. 1999).published (Whether the appellants' expert might have done a better job is not the test.)
- 22 Emp. Benefits Cas. 2945, Pens. Plan Guide (Cch) P 23952e, 173 F.3d 145 (3d Cir. 1992).published (Whether the appellants' expert might have done a better job is not the test.)
- Matlin v. Langkow, 65 F. App'x 373 (3d Cir. 2003).unpublished(If the expert meets liberal minimum qualifications, then the level of the expert’s expertise goes to credibility and weight, not admissibility.)
- Silipena v. Am. Pulverizer Co., No. 1:16-cv-00711 (D.N.J. June 28, 2024).Pa. 2002). “[I]f the expert meets the liberal, minimum qualifications then the level of the expert’s expertise goes to credibility and weight, not admissibility.” Kannankeril v. Terminix Int’l Inc., 128 F.3d 802, 809 (3d Cir. 1997)(citing…
Show 53 more citing cases
- Nat'l Fire & Marine Ins. Co. v. Newtown Square, LLC, No. 2:21-cv-05397 (E.D. Pa. Apr. 18, 2024).“If the expert meets the liberal minimum qualifications, then the level of the expert’s expertise goes to credibility and weight, not admissibility.” Kannankeril v. Terminix Int'l, Inc., 128 F.3d 802, 809 (3d Cir. 1997).
- United States v. G&C Fab-con, LLC, No. 3:20-cv-02968 (D.N.J. Feb. 14, 2024).unpublishedNov. 6, 2023) (quoting Kannankeril v. Terminix Int’l, Inc., 128 F.3d 802, 809 (3d Cir. 1997), as amended (Dec. 12, 1997)).
- US Sugar Corp. v. Henson, 787 So. 2d 3 (Fla. 1st DCA 2001).published
- Ruff v. Ensign-bickford Indus., Inc., 171 F. Supp. 2d 1226 (D. Utah 2001).published
- Gov't of the Virgin Islands v. Greenidge, 41 V.I. 200 (D.V.I. 1998).published
- Wolfe v. McNeil-PPC, Inc., 881 F. Supp. 2d 650 (E.D. Pa. 2012).published
- Lewis v. Gov't Employees Ins. Co., No. 1:18-cv-05111, 2022 WL 819611 (D.N.J. Mar. 18, 2022).
- Equinox Props., LLC v. Harford Mut. Ins. Co., No. 1:21-cv-15929, 2023 WL 5447279 (D.N.J. Aug. 24, 2023).
- Failla v. George's Foods, LLC, No. 2:20-cv-07109, 2023 WL 7298473 (D.N.J. Nov. 6, 2023).unpublished
- Arcuri v. Cnty. of Montgomery, No. 2:20-cv-05408 (E.D. Pa. Aug. 16, 2022).
- United States v. Fleet Mgmt., Ltd., 332 F. App'x 753 (3d Cir. 2009).unpublished
- United States v. Richard Junior Frazier, 387 F.3d 1244 (11th Cir. 2004).published
- United States v. Richard Stadtmauer, 620 F.3d 238 (3d Cir. 2010).published
- Carol Heller v. Shaw Indus., Inc., 167 F.3d 146 (3d Cir. 1999).published
- Fred Lauzon v. Senco Prods., Inc., 270 F.3d 681 (8th Cir. 2001).published
- Smolow v. Hafer, 513 F. Supp. 2d 418 (E.D. Pa. 2007).published
- In re Exide Tech., 340 B.R. 222 (Bankr. D. Del. 2006).published
- Pfizer Inc. v. Teva Pharm. USA, Inc., 460 F. Supp. 2d 659 (D.N.J. 2006).published
- Pfizer Inc. v. Teva Pharm. USA, Inc., 461 F. Supp. 2d 271 (D.N.J. 2006).published
- In re Williams Sec. Litig., 496 F. Supp. 2d 1195 (N.D. Okla. 2007).published
- Louderback v. Orkin Exterminating Co., 26 F. Supp. 2d 1298 (D. Kan. 1998).published
- Suter v. Gen. Accident Ins. Co. of Am., 424 F. Supp. 2d 781 (D.N.J. 2006).published
- United States v. Vaghari, 735 F. Supp. 2d 197 (E.D. Pa. 2010).published
- Graves v. Mazda Motor Corp., 675 F. Supp. 2d 1082 (W.D. Okla. 2009).published
- Mascarenas v. Cooper Tire & Rubber Co., 643 F. Supp. 2d 1363 (S.D. Ga. 2009).published
- State ex rel. Montgomery v. Miller, 321 P.3d 454 (Ariz. Ct. App. 2014).published
- Glazer v. State, 321 P.3d 470 (Ariz. Ct. App. 2014).published
- State of Arizona v. Manuel Alejandro Delgado, 303 P.3d 76 (Ariz. Ct. App. 2013).published
- United States v. Phung, 127 F. App'x 594 (3d Cir. 2005).unpublished
- State v. Meyer, No. 1 CA-CR 15-0290 (Ariz. Ct. App. July 7, 2016).unpublished
- Hall v. Flannery, 840 F.3d 922 (7th Cir. 2016).published
- State v. Tull, No. 1 CA-CR 15-0591 (Ariz. Ct. App. July 20, 2017).unpublished
- Elizabeth Snider v. Sterling Airways, No. 17-3182 (3d Cir. Dec. 28, 2018).unpublished
- Michael H Bernardi v. Tonya Melynda Rock, No. 347134 (Mich. Ct. App. June 18, 2020).unpublished
- State Nat'l Ins. v. Cnty. of Camden, 10 F. Supp. 3d 568 (D.N.J. 2014).published
- Campbell v. Fawber, 975 F. Supp. 2d 485 (M.D. Pa. 2013).published
- Leonard v. Stemtech Health Sciences, Inc., 981 F. Supp. 2d 273 (D. Del. 2013).published
- Hendrix v. Evenflo Co., 255 F.R.D. 568 (N.D. Fla. 2009).published
- PSB Indus., Inc. v. Costanzo's Welding, Inc., 276 F.R.D. 184 (W.D. Pa. 2011).published
- Carnegie Mellon Univ. v. Marvell Tech. Grp., Ltd., 286 F.R.D. 266 (W.D. Pa. 2012).published
- Otsuka Pharm. Co. v. Zenara Pharma Private Ltd., No. 1:19-cv-01938 (D. Del. Sept. 21, 2022).
- Wertheimer H. v. Ridley USA, No. 4:18-cv-00083 (D. Mont. Feb. 28, 2020).
- United States v. Johnson & Johnson, No. 3:12-cv-07758 (D.N.J. Jan. 10, 2022).unpublished
- Rullo v. Univ. of Pittsburgh--of the Commonwealth Sys. of Higher Educ., 520 F. Supp. 3d 685 (W.D. Pa. 2021).published
- Bernard v. BNY Mellon, No. 2:18-cv-00783 (W.D. Pa. Feb. 7, 2022).
- Strictly f/x L.L.C. v. Pyrotecnico Fireworks, Inc., No. 2:20-cv-00201 (W.D. Pa. June 29, 2022).
- Frobe v. UPMC St. Margaret, No. 2:20-cv-00957 (W.D. Pa. May 31, 2023).
- Graystone Funding v. Network Funding, 598 F. Supp. 3d 1228 (D. Utah 2022).published
- State of Wisconsin v. Indivior Inc., No. 2:16-cv-05073 (E.D. Pa. Feb. 19, 2021).
- Greenwald Caterers Inc v. Lancaster Host LLC, 699 F. Supp. 3d 382 (E.D. Pa. 2023).published
- Walden v. Bank of New York Mellon Corp., No. 2:20-cv-01972 (W.D. Pa. Jan. 30, 2024).
- Dandy v. Ethicon Women's Health & Urology, No. 3:20-cv-00431 (D.N.J. Mar. 30, 2023).unpublished
- Novaplast Corp. v. Inplant, LLC, No. 2:20-cv-07396 (D.N.J. Dec. 15, 2025).
At page 807 Expert testimony and physician reliance on other medical tests62 citing casesexplaining that "[d]ifferential diagnosis is defined for physicians as 'the determination of which of two or more diseases with similar symptoms is the one from which the patient is suffering, by a systematic comparison and contrasting of the clinical findings'
- Miretskaya v. Rutgers, No. 3:20-cv-14856 (D.N.J. July 29, 2022).unpublished ([]t is perfectly acceptable, in arriving at a diagnosis, for a physician to rely > In his opposition brief, Miretskaya includes factual allegations that appear nowhere in the Amended Complaint or its exhibits, includin…)
- Pritchard v. Dow Agro Sciences, 705 F. Supp. 2d 471 (W.D. Pa. 2010).published Co., 80 F.3d 777, 782 (3d Cir.1996)); see also Kannankeril, 128 F.3d at 809 (“We reject [defendant’s] suggestion that [the doctor] must be an expert in Dursban to provide expert testimony on the causation of [plaintiffs] injury.”).
- Brown v. Fisher-Price, Inc., No. N20C-01-067 PAW (Del. Super. Ct. Dec. 20, 2024).publishedSuper. 2006). 58 Id. 59 Id. (internal quotations omitted) (quoting Kannakeril v. Terminix Intern., Inc., 128 F.3d 802, 807 (3d Cir. 1997)). 60 Id. (internal quotations omitted) (quoting Poust v. Huntleigh Healthcare, 998 F.Supp. 478, 496 (…
- Bowers v. Nat'l Collegiate Athletic Ass'n, 564 F. Supp. 2d 322 (D.N.J. 2008).published
- Hamilton v. Emerson Elec. Co., 133 F. Supp. 2d 360 (M.D. Pa. 2001).published
- Magistrini v. One Hour Martinizing Dry Cleaning, 180 F. Supp. 2d 584 (D.N.J. 2002).published
- Ellison v. United States, 753 F. Supp. 2d 468 (E.D. Pa. 2010).published
- James Curtis Westberry, & Connie Rena Westberry v. Gislaved Gummi Ab, & Mataki Kemi Ab, Connie Rena Westberry, & James Curtis Westberry v. Gislaved Gummi Ab, & Mataki Kemi Ab, 178 F.3d 257 (4th Cir. 1999).published
- Cooper v. Smith & Nephew, Inc., 259 F.3d 194 (4th Cir. 2001).published
- Gregory Johnson v. Arkema, Inc., 685 F.3d 452 (5th Cir. 2012).published
Show 48 more citing cases
- Gregory Johnson v. Arkema, Inc., No. 11-50193 (5th Cir. June 26, 2012).published
- Carlson v. Okerstrom, 675 N.W.2d 89 (Neb. 2004).published
- Coastal Tankships, U.S.A., Inc. v. Anderson, 87 S.W.3d 591 (Tex. App.—Houston [1st Dist.] 2002).published
- Praytor v. Ford Motor Co., 97 S.W.3d 237 (Tex. App.—Houston [14th Dist.] 2002).published
- Feit v. Great-West Life & Annuity Ins. Co., 460 F. Supp. 2d 632 (D.N.J. 2006).published
- Voilas v. Gen. Motors Corp., 73 F. Supp. 2d 452 (D.N.J. 1999).published
- Hall v. Babcock & Wilcox Co., 69 F. Supp. 2d 716 (W.D. Pa. 1999).published
- State v. McMullen, 900 A.2d 103 (Del. Super. Ct. 2006).published
- Steinhilber v. McCarthy, 26 F. Supp. 2d 265 (D. Mass. 1998).published
- Lennon v. Norfolk & W. Ry. Co., 123 F. Supp. 2d 1143 (N.D. Ind. 2000).published
- Caldwell v. Dist. of Columbia, 201 F. Supp. 2d 27 (D.D.C. 2001).published
- Plourde v. Gladstone, 190 F. Supp. 2d 708 (D. Vt. 2002).published
- Eng v. Klein, 110 P.3d 844 (Wash. Ct. App. 2005).published
- Nield v. Pocatello Health Servs., Inc., 332 P.3d 714 (Idaho 2014).published
- Judy Nield v. Pocatello Health Servs. (Idaho 2014).published
- Judy Nield v. Pocatello Health Servs. (Idaho 2014).published
- Coastal Tankship, U.S.A., Inc. v. Florence Anderson, No. 01-99-01345-CV (Tex. App.—Houston [1st Dist.] May 31, 2002).published
- United States v. Fleet Mgmt., Ltd., 332 F. App'x 753 (3d Cir. 2009).unpublished
- Price v. Sec'y of Health & Human Servs., No. 11-442, 2015 WL 7423070 (Fed. Cl. Nov. 23, 2015).published
- United States v. Rafael Chikvashvili, 859 F.3d 285 (4th Cir. 2017).published
- Culler v. Bayhealth Med. Ctr., Inc., No. K16C-07-013 NEP (Del. Super. Ct. Apr. 16, 2018).published
- A. v. Sec'y of Health & Human Servs., No. 11-51 (Fed. Cl. Jan. 10, 2019).published
- Taylor v. Norfolk S. Ry. Co., 2020-Ohio-2657.published
- Hicks's Case, 820 N.E.2d 826 (Mass. App. Ct. 2005).published
- Westberry v. Gislaved Gummi AB, 178 F.3d 257 (4th Cir. 1999).published
- Tyree v. Boston Sci. Corp., 54 F. Supp. 3d 501 (S.D. W. Va. 2014).published
- Eghnayem v. Boston Sci. Corp., 57 F. Supp. 3d 658 (S.D. W. Va. 2014).published
- Hempstead v. Pfizer, Inc., 150 F. Supp. 3d 644 (D.S.C. 2015).published
- In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices & Prods. Liab. Litig., 185 F. Supp. 3d 786 (D.S.C. 2016).published
- Dale v. State, No. 145, 2022 (Del. July 19, 2023).published
- Warren v. United States, 524 F. Supp. 3d 1068 (D. Haw. 2021).published
- Mathis v. Garrison Prop. & Cas. Ins. Co., No. 2:18-cv-10100 (E.D. La. June 28, 2019).
- Lemberger v. Union Pac. R.R. Co., 463 F. Supp. 3d 954 (D. Neb. 2020).published
- Langrell v. Union Pac. R.R. Co., No. 8:18-cv-00057 (D. Neb. June 5, 2020).
- Edgett v. Union Pac. R.R. Co., No. 8:18-cv-00407, 2021 WL 1238498 (D. Neb. Apr. 1, 2021).
- Warren Hill, LLC v. Neptune Investors, LLC, No. 2:20-cv-00452 (E.D. Pa. May 20, 2021).
- Miller v. Bgha, Inc., No. 2:19-cv-01293 (E.D. Pa. June 30, 2021).
- Elmegreen v. Merck & Co., No. 2:17-cv-02044-HB (E.D. Pa. Dec. 1, 2021).
- Sansone v. Merck & Co., No. 2:18-cv-20114 (E.D. Pa. Dec. 1, 2021).
- Bush v. Merck & Co., No. 2:19-cv-01117 (E.D. Pa. Dec. 1, 2021).
- Niedzialowski v. Merck & Co., No. 2:19-cv-20025 (E.D. Pa. Dec. 1, 2021).
- Doman v. Merck & Co Inc, No. 2:18-cv-20118 (E.D. Pa. Dec. 1, 2021).
- Scicchitano Smith v. SPECTRUM BRANDS, INC., No. 2:21-cv-04983 (E.D. Pa. Aug. 10, 2022).
- Am. Strategic Ins. Corp. v. Michael W. Lohman LLC, No. 2:22-cv-02837 (E.D. Pa. Sept. 8, 2023).
- Bockus v. Merck & Co., No. 2:18-cv-20020 (E.D. Pa. Oct. 11, 2023).
- Bell v. Farrell, No. 4:17-cv-02020 (M.D. Pa. July 10, 2020).
- Ezeibe v. City of York, No. 1:19-cv-00189 (M.D. Pa. Mar. 24, 2022).
- Johnson v. Nault, No. 4:20-cv-00060 (D. Utah June 17, 2022).
At page 808 Assessing expert testimony reliability using scientific knowledge17 citing casesholding trial court erred in excluding expert's testimony when opinion supported by differential diagnosis, temporal proximity, and reading of standard textbooks and references; however, "widely accepted scientific knowledge of nature of" chemical's toxicity existed
- Pritchard v. Dow Agro Sciences, 705 F. Supp. 2d 471 (W.D. Pa. 2010).published Co., 80 F.3d 777, 782 (3d Cir.1996)); see also Kannankeril, 128 F.3d at 809 (“We reject [defendant’s] suggestion that [the doctor] must be an expert in Dursban to provide expert testimony on the causation of [plaintiffs] injury.”).
- Fitzgerald v. Catholic Health Initiatives Colorado, No. 1:21-cv-00006 (D. Colo. Apr. 18, 2025).LP, 602 F.3d 1245, 1253 (11th Cir. 2010) (quoting Kannankeril v. Terminix Int’l, Inc., 128 F.3d 802, 808 (3d Cir.1997))).
- Boncher v. 3M Co., No. 5:24-cv-01403 (E.D. Pa. Feb. 14, 2025). Pa. Apr. 18, 2024) (citing Kannankeril v. Terminix Int'l, Inc., 128 F.3d 802, 806 (3d Cir. 1997), as amended (Dec. 12, 1997)).
- Bowers v. Nat'l Collegiate Athletic Ass'n, 564 F. Supp. 2d 322 (D.N.J. 2008).published
- Coastal Tankships, U.S.A., Inc. v. Anderson, 87 S.W.3d 591 (Tex. App.—Houston [1st Dist.] 2002).published
- Voilas v. Gen. Motors Corp., 73 F. Supp. 2d 452 (D.N.J. 1999).published
- Coastal Tankship, U.S.A., Inc. v. Florence Anderson, No. 01-99-01345-CV (Tex. App.—Houston [1st Dist.] May 31, 2002).published
- Wicker v. Consol. Rail Corp., 371 F. Supp. 2d 702 (W.D. Pa. 2005).published
- Perkins v. Origin Medsystems Inc., 299 F. Supp. 2d 45 (D. Conn. 2004).published
- Alder v. Bayer Corp., 2002 UT 115, 61 P.3d 1068.published
Show 7 more citing cases
- McMunn v. Babcock & Wilcox Power Generation Grp., Inc., 869 F.3d 246 (3d Cir. 2017).published
- Great Am. Ins. Co. of New York v. Compass Well Servs., LLC, No. 02-19-00373-CV (Tex. App.—Fort Worth Dec. 17, 2020).published
- Huskey v. Ethicon, Inc., 29 F. Supp. 3d 691 (S.D. W. Va. 2014).published
- Hoefling v. Altria Grp., Inc., No. 2:19-cv-03847 (E.D. Pa. Dec. 21, 2021).
- Saldana v. Delta Airlines, Inc., No. 1:19-cv-00027 (D.V.I. Oct. 8, 2021).
- Allen v. Am. Cyanamid Co, 527 F. Supp. 3d 982 (E.D. Wis. 2021).published
- Trammell v. Am. Cyanamid Co, No. 2:14-cv-01423 (E.D. Wis. Mar. 22, 2021).
At page 805 Trial judge's gatekeeping role in expert testimony5 citing cases
- Kaisinger v. Walmart Stores, Inc., No. 2:18-cv-00855 (E.D. Pa. Apr. 9, 2024).The trial judge serves as a gatekeeper who ensures “that any and all expert testimony or evidence is not only relevant but also reliable.” Kannankeril v. Terminix Int’l, 128 F.3d 802, 805 (3d Cir. 1997) (citing Daubert, 509 U.S. at 589 ).
- Slatowski v. SIG SAUER, INC., No. 2:21-cv-00729, 2024 WL 1078198 (E.D. Pa. Mar. 12, 2024).The trial judge serves as a 1 The Solicitation also specifies that the gun “shall not have a magazine disconnect which prevents the firearm from firing when the magazine is removed from the pistol” and “shall not have an gatekeeper who ens…
- Moore v. Ashland Chem. Inc., 151 F.3d 269 (5th Cir. 1998).published
- US Sugar Corp. v. Henson, 787 So. 2d 3 (Fla. 1st DCA 2001).published
- In re TMI Litig., 193 F.3d 613 (3d Cir. 1999).
In attacking the differential diagnosis performed by the plaintiff's expert, the defendant may point to a plausible cause of the plaintiff's illness other than the defendant's actions.
- In re Testosterone Replacement Therapy Prods. Liab. Litig., No. 1:14-cv-01748 (N.D. Ill. Nov. 1, 2023). (In attacking the differential diagnosis performed by the plaintiff's expert, the defendant may point to a plausible cause of the plaintiff's illness other than the defendant's actions.)
- Davis v. Actavis, Inc., No. 1:17-cv-03775 (N.D. Ill. Nov. 1, 2023). (In attacking the differential diagnosis performed by the plaintiff's expert, the defendant may point to a plausible cause of the plaintiff's illness other than the defendant's actions.)
Rule 702 . . . has a liberal policy of admissibility.
- Lontex Corp. v. Nike, Inc., No. 2:18-cv-05623 (E.D. Pa. Mar. 25, 2021).(Rule 702 . . . has a liberal policy of admissibility.)
- Ashton Woods Holdings L.L.C. v. USG Corp., No. 2:15-cv-01712 (E.D. Pa. Apr. 7, 2020).(Rule 702 . . . has a liberal policy of admissibility.)
Other citing cases
- Johnson v. Comodo Grp., Inc., No. 2:16-cv-04469, 2024 WL 2933195 (D.N.J. June 10, 2024).unpublished
v.
Terminix International, Inc. Tm Special Partners, Inc. Terminix Mgp, Inc., General Partners of the Terminix International Company Limited Partnership Terminix International Dow Chemical U.S.A. Whitmire Research Laboratories, Inc. Ford Chemical & Service, Inc. Dennis Buttimore, C/o Terminix International the Terminix International Company Limited Partnership Mary Kannankeril, Individually and as Next Friend of Charlene Kannankeril
28 Envtl. L. Rep. 20,219, 47 Fed. R. Evid.
Serv. 1376,
Prod.Liab.Rep. (CCH) P 15,089
Charles KANNANKERIL; Mary Kannankeril, individually and as
next friend of Charlene and Crystal Kannankeril;
Charlene Kannankeril; Crystal Kannankeril
v.
TERMINIX INTERNATIONAL, INC.; TM Special Partners, Inc.;
Terminix MGP, Inc., General Partners of the Terminix
International Company Limited Partnership; Terminix
International; Dow Chemical U.S.A.; Whitmire Research
Laboratories, Inc.; Ford Chemical & Service, Inc.; Dennis
Buttimore, c/o Terminix International; The Terminix
International Company Limited Partnership
Mary Kannankeril, Individually and as Next Friend of
Charlene Kannankeril, Appellant.
No. 96-5818.
United States Court of Appeals,
Third Circuit.
Argued July 17, 1997.
Decided Oct. 17, 1997.
As Amended Dec. 12, 1997.
Evan T. Lawson (argued), Christopher N. Cook, Lawson & Weitzen, Boston, MA, for Appellants.
Kevin E. Wolff (argued), Robert W. Muilenburg, McElroy, Deutsch & Mulvaney, Morristown, NJ, for Appellee Terminix International.
Before: SLOVITER, Chief Judge, ROTH and MICHEL,[1] Circuit Judges.
OPINION OF THE COURT
ROTH, Circuit Judge.
The Kannankerils, Dr. Mary Kannankeril, her husband, Charles, and their children, Charlene and Crystal, sued a pest exterminator, the Terminix International Company L.P. ("Terminix"), seeking damages for injuries allegedly arising out of the application of pesticides to their residence. The district court found the opinion of Dr. Benjamin Gerson, the medical expert of Dr. Mary Kannankeril, to be unreliable and unsupported by facts. Having excluded Dr. Gerson's opinion, the district court held that Dr. Kannankeril had failed to produce any evidence that her cognitive impairment had been caused by exposure to pesticides applied by Terminix. The court granted summary judgment in favor of Terminix. The admissibility of Dr. Gerson's opinion is the sole issue on which the Kannankerils have appealed. They argue that the district court erroneously excluded the testimony of Dr. Gerson.
We conclude that the district court improperly exercised its gatekeeping role by excluding Dr. Gerson's testimony.
Accordingly, we will vacate that portion of the order of the district court, granting summary judgment against Dr. Mary Kannankeril on this point, and we will remand this case for further proceedings consistent with this opinion.[2]
I. BACKGROUND
The Kannankerils entered into a one-year contract with Terminix on May 30, 1989, for the control of carpenter ants through the application of pesticides to certain interior portions and the outside deck of the Kannankerils' residence. From May 31, 1989, through October 5, 1990, Terminix treated the Kannankeril residence on at least twenty occasions at intervals ranging from once a month to twice in a three day period. Terminix applied pesticides, containing Dursban, until the Kannankerils canceled the service on October 5, 1990.
Dursban, the active ingredient in certain pesticides used by Terminix, is a formulation of chlorpyrifos, an organophosphate poison. The organophosphates kill insects by inhibiting the normal breakdown of acetylcholine, which functions as a neurotransmitter in several life forms, including humans. The Kannankerils argue that despite the well-known chronic effects of chlorpyrifos, Dursban was sprayed excessively and improperly in their home. For example, Dursban was sprayed on the cooking range, around the dishwasher, and on the baseboard heater. Dursban was also sprayed in cupboards where pots and pans were stored. Terminix, however, claims that any liquid pesticide that was applied consisted almost entirely of water, with minute concentrations of liquid pesticide added to make the final active solution.
The Kannankerils' suit against Terminix involved alleged injury to Dr. Mary Kannankeril, a former Medical Director of Psychiatric Emergency Services at Saint Mary's Hospital in Passaic, New Jersey. Dr. Kannankeril claims to suffer wide-ranging physiological and cognitive symptoms from exposure to the pesticides, including Dursban, applied by Terminix.[3] The symptoms first appeared in August 1990, over one year after Terminix began its service. The Kannankerils did not relate Dr. Kannankeril's symptoms with Terminix's ongoing pesticide applications until October 1990. After the entire family developed a rash, the Kannankerils began to suspect Dursban as the cause of their problems. When the Kannankerils complained of a strong odor in their home after the last application, Terminix sent Service Master to clean the Kannankerils' residence. In July 1991, nine months after the last application of pesticide, the Kannankerils requested that the New Jersey Department of Environmental Protection ("DEP") test their residence for the existence of pesticides. The DEP collected air samples from the residence on July 10, 1991. An analysis of the samples indicated nondetectable levels of pesticides.
Dr. Kannankeril allegedly developed chronic toxicity related to exposure to chlorpyrifos and became sensitized to multiple other chemicals so that further exposure to organophosphates would result in disabling physical problems. As a result of her ill health, she gave up her hospital position in March, 1993, and now sees patients only in an office at home.
Plaintiffs named Dr. Benjamin Gerson, M.D., to testify as a medical expert to establish that exposure to Dursban caused Dr. Kannankeril's injury.[4] Dr. Gerson provided the following opinion:
The temporal relationship and the nature of her complaints lead me to conclude that with reasonable medical certainty, the cause of Dr. Kannankeril's Central Nervous System manifestations of toxicity is exposure to Dursban in 1989 to 1990.
App. at 51.[5] Dr. Gerson is the only medical expert proffered by the Kannankerils on causation and his opinion is limited to the causation of Dr. Kannankeril's cognitive impairment. His findings are based on Dr. Kannankeril's account of her cognitive symptoms and on a report prepared by Dr. Ellen Grober, a neuropsychologist who examined Dr. Kannankeril. Dr. Gerson also relied on a summary report of the times and amounts of Dursban applications to the Kannankeril home as well as on his general experience and readings, general medical knowledge, standard textbooks, and standard references.
II. STANDARD OF REVIEW
A district court's ruling on admissibility of expert testimony is reviewed for abuse of discretion. Government of the Virgin Islands v. Sanes, 57 F.3d 338, 341 (3d Cir.1995); In re Paoli R.R. Yard PCB Litig., 35 F.3d 717, 749 (3d Cir.1994). To the extent that the district court's ruling turns on interpretation of the Federal Rules of Evidence, our review is plenary. United States v. Velasquez, 64 F.3d 844, 848 (3d Cir.1995); Paoli, 35 F.3d at 749. We review the district court's findings of fact under a clearly erroneous standard. Velasquez, 64 F.3d at 848.
III. DISCUSSION
A. Standard of Admissibility for Expert Testimony
Under the Federal Rules of Evidence, it is the role of the trial judge to act as a "gatekeeper" to ensure that any and all expert testimony or evidence is not only relevant, but also reliable. Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 589, 113 S.Ct. 2786, 2794-95, 125 L.Ed.2d 469. (1993). The Rules of Evidence embody a strong and undeniable preference for admitting any evidence which has the potential for assisting the trier of fact. See Holbrook v. Lykes Bros. S.S. Co., 80 F.3d 777, 780 (3d Cir.1996). Rule 702, which governs the admissibility of expert testimony, has a liberal policy of admissibility. See Holbrook, 80 F.3d at 780; Paoli, 35 F.3d at 741.
Rule 702 has three major requirements: (1) the proffered witness must be an expert; (2) the expert must testify about matters requiring scientific, technical or specialized knowledge; and (3) the expert's testimony must assist the trier of fact. See Paoli, 35 F.3d at 741-42. The issue of this appeal involves the second requirement of the expert's testimony. In interpreting this second requirement, we have concluded that "an expert's testimony is admissible so long as the process or technique the expert used in formulating the opinion is reliable." Id. at 742 (citing Daubert, 509 U.S. at 589, 113 S.Ct. at 2794-95). In order for the expert testimony to be "reliable," we have required that the testimony be based on the "methods and procedures of science," rather than on "subjective belief or unsupported speculation." Paoli, 35 F.3d at 744. Moreover, Daubert does not set up a test of which opinion has the best foundation, but rather whether any particular opinion is based on valid reasoning and reliable methodology. Admissibility decisions focus on the expert's methods and reasoning; credibility decisions arise after admissibility has been determined. See Paoli, 35 F.3d at 743-46.
There are several factors that a district court should take into account in evaluating whether a particular scientific methodology is reliable. See Paoli, 35 F.3d at 742.[6] Although these factors are neither exhaustive nor applicable in every case, they provide a convenient starting point for analyzing the opinion of Dr. Gerson. Our inquiry focuses on principles and methodology and not on the conclusions they generate. Id. at 744. The analysis of the conclusions themselves is for the trier of fact when the expert is subjected to cross-examination. Id. The Kannankerils needed to demonstrate by a preponderance of evidence only that Dr. Gerson's opinion was based on "good grounds." Id.
B. Reliability of Dr. Gerson's Testimony
The district court refused to admit Dr. Gerson's testimony because of insufficient factual foundation to prove that the cause of Dr. Kannankeril's cognitive impairment was exposure to Dursban. We conclude, however, that Dr. Gerson's opinion meets the requirements for the admission of expert testimony under Rule 702 of the Federal Rules of Evidence, as set forth in Daubert and interpreted by us in Paoli.
1. Differential Diagnosis
In its opposition to Dr. Gerson's testimony, Terminix has emphasized that Dr. Gerson did not himself perform any diagnostic medical tests. Terminix argues that Dr. Gerson did not employ sufficient diagnostic techniques to have good grounds for his conclusions or to have properly performed a differential diagnosis. We have recognized "differential diagnosis" as a technique that involves assessing causation with respect to a particular individual. Paoli, 35 F.3d at 758. Differential diagnosis is defined for physicians as "the determination of which of two or more diseases with similar symptoms is the one from which the patient is suffering, by a systematic comparison and contrasting of the clinical findings." STEDMAN'S MEDICAL DICTIONARY 428 (25th ed.1990). The elements of a differential diagnosis may consist of the performance of physical examinations, the taking of medical histories, and the review of clinical tests, including laboratory tests. A doctor does not have to employ all of these techniques in order for the doctor's diagnosis to be reliable. See Paoli, 35 F.3d at 759. A differential diagnosis may be reliable with less than all the types of information set out above. See id. Indeed, as we held in Paoli, "to the extent that the district court concluded otherwise [i.e., that a differential diagnosis made on less than all types of information cannot be reliable], we hold that it abused its discretion." Id.
Depending on the medical condition at issue and on the clinical information already available, a physician may reach a reliable differential diagnosis without himself performing a physical examination, particularly if there are other examination results available. In fact, it is perfectly acceptable, in arriving at a diagnosis, for a physician to rely on examinations and tests performed by other medical practitioners.
These principles are applicable to the admissibility of Dr. Gerson's expert opinion regarding Dr. Kannankeril. The district court found that Dr. Gerson never performed any clinical tests to support his opinion of causation. Dr. Gerson did not "examine, or even speak to" Dr. Kannankeril. Instead, Dr. Gerson reviewed the records of Dr. Kannankeril's medical history. Dr. Gerson also relied on Dr. Grober's report of Dr. Kannankeril's neuropsychological complaints and of her cognitive impairment. Terminix does not claim that the medical records relied upon by Dr. Gerson were incomplete or inaccurate. As noted by this Court in Paoli, "evaluation of the patient's medical records is a reliable method of concluding that a patient is ill even in the absence of a physical examination." Id. at 762. A doctor needs only one reliable source of information showing that a plaintiff is ill; either a physical test or medical records will suffice for this. Id. at 762. For these reasons, the reliability of Dr. Gerson's opinion is not necessarily diminished by the fact that he himself did not perform a physical examination.
Moreover, in making his evaluation, Dr. Gerson was aware that one test, the cholinesterase blood test, did not produce abnormal results. The district court noted that the blood test for cholinesterase levels is "the most accepted test method for determining exposure to Dursban." However, the cholinesterase test result is but one of the factors considered by Dr. Gerson. Despite the negative results from this test, Dr. Gerson still opined that, as a matter of reasonable medical certainty, Dursban had caused Dr. Kannankeril's cognitive impairment. It is for the jury to decide whether a single cholinesterase test, yielding results within normal limits, outweighs the other factors relied upon by Dr. Gerson and undermines his opinion. This is an issue of credibility, not of admissibility.
Furthermore, we do not agree with the trial court's finding that "every" objective medical test showed normal results. The cholinesterase test was not the only clinical test performed on Dr. Kannankeril. Dr. Grober, the neuropsychologist at the Albert Einstein Medical Center, confirmed a diminution in Dr. Kannankeril's cognitive abilities.
In attacking the differential diagnosis performed by the plaintiff's expert, the defendant may point to a plausible cause of the plaintiff's illness other than the defendant's actions. It then becomes necessary for the plaintiff's expert to offer a good explanation as to why his or her conclusion remains reliable. Paoli, 35 F.3d at 762. Dr. Gerson, however, was never challenged by the presentation of alternate diagnoses by other physicians. Moreover, Terminix, in challenging Dr. Gerson's opinion, has not raised any other theory of causation for Dr. Kannankeril's cognitive impairment.[7] The record in this case is devoid of any alternate diagnosis which Dr. Gerson ignored or failed to consider.
Furthermore, we reject Terminix's argument that Dr. Gerson admitted to alternate causes other than exposure to Dursban for Dr. Kannankeril's condition. Dr. Gerson had testified at his deposition that something other than exposure to organophosphates "could" have caused each of the individual symptoms displayed by Dr. Kannankeril. While, however, an alternate explanation for each of Dr. Kannankeril's individual symptoms may exist separately, Dr. Gerson concluded with reasonable medical certainty that Dursban was the most likely cause of her condition as a whole. Terminix's exploration of the cause of each individual symptom goes not to the admissibility of the evidence but to its weight.
2. Degree of Exposure
The Kannankerils also contend that the district erred in finding that Dr. Gerson had no knowledge of Dr. Kannankeril's degree of exposure to Dursban. According to the district court, Dr. Gerson did not know the levels of Dursban at the Kannankerils' home at the time of exposure, and he did not know the amount of time plaintiffs spent in the home. We conclude, however, that the district court erred when it failed to recognize that Dr. Gerson had sufficient knowledge of exposure from his review of Terminix's application records, showing when, how much, and where pesticide had been applied.
Terminix asserts, however, that these application records are "unreliable as a matter of law as a tool" to determine Dr. Kannankeril's exposure. The trial court agreed and ruled that the only information reviewed by Dr. Gerson which addressed actual levels of pesticides in the Kannankeril home was the analysis performed by the DEP in July 1991, nine months after the last application of Dursban. The results of that sampling indicated nondetectable levels of pesticides.
We find that Terminix's assertion is without merit. First, there is no expert opinion in the record to establish that an ambient air test, particularly an ambient air test performed nine months after the final application of Dursban, is the only appropriate way in this case to gauge exposure to the organophosphate. Moreover, the plaintiffs were prepared to offer into evidence the Dursban product label which contained warnings such as: "HARMFUL IF SWALLOWED. HARMFUL IF ABSORBED THROUGH SKIN. CAUSES EYE AND SKIN IRRITATION" and "Thoroughly wash dishes and food handling utensils with soap and water if they become contaminated by application of this product. Do not allow children or pets to contact treated surfaces until spray has dried." App. at 241-43. Under the facts as presented in this case, the district judge erred in ruling that an expert may rely only on the ambient air test to determine whether Dr. Kannankeril had been exposed to Dursban. Instead, all factual evidence of the presence of the chemicals in the residence should be relevant in forming an expert opinion of causation.
We conclude that it is for the trier of fact to determine what weight to give the ambient air test results as an indication of exposure. See Joiner v. General Elec. Co., 78 F.3d 524, 534 (11th Cir.1996) (reversing exclusion of expert opinions that plaintiffs' exposure to certain chemicals caused his lung cancer where there were issues of fact whether plaintiff was actually exposed to the chemicals so that summary judgment based on a finding of no exposure was inappropriate). The issue whether an ambient air test should be given more weight than pesticide application records goes to the weight rather than the admissibility of evidence. See United States v. Velasquez, 64 F.3d 844, 848 (3d Cir.1995) (citing United States v. Jakobetz, 955 F.2d 786, 800 (2d Cir.1992)). The trial judge must be careful not to mistake credibility questions for admissibility questions.
3. Peer Review and Publication
Two other factors that a district court can take into account in assessing reliability are peer-review and publication. They may not, however, in every case be necessary conditions of reliability. See Daubert, 509 U.S. at 593, 113 S.Ct. at 2796-97; Paoli, 35 F.3d at 742. In the instant case, Dr. Gerson admitted that he has not produced any publication on organophosphates. Because the toxic effects of organophosphates on humans are well recognized by the scientific community, however, Dr. Gerson's opinion is not a novel scientific theory regarding organophosphates.[8] Instead, Dr. Gerson merely reported that Dr. Kannankeril exhibited the "signs and symptoms of chronic toxicity related to exposure to chlorpyrifos (Dursban)." Thus, although Dr. Gerson did not write on the topic, his opinion is supported by widely accepted scientific knowledge of the harmful nature of organophosphates. See also McCullock v. H.B. Fuller Co., 61 F.3d 1038, 1042 (2d Cir.1995) (holding that peer review and publication or general acceptance of an expert's theory goes to the weight of the testimony rather than its admissibility).
Based on the record before us, we conclude that Dr. Gerson's opinion on causation has a factual basis and supporting scientific theory. Dr. Gerson based his opinion on Dr. Kannankeril's medical records, Dr. Grober's reports confirming her medical condition, and Terminix's application receipts. He also relied on general experience and readings, general medical knowledge, standard textbooks, and standard references. After considering all the relevant facts, Dr. Gerson reported that "[t]he temporal relationship and the nature of her complaints lead me to conclude that with reasonable medical certainty, the cause of Dr. Kannankeril's Central Nervous System manifestations of toxicity is exposure to Dursban in 1989 to 1990." App. at 51. Dr. Gerson's testimony is neither conjecture nor speculation. His opinion was clearly stated to a reasonable degree of medical certainty.
Whether the appellants' expert might have done a better job is not the test. We have stated that "it is an abuse of discretion to exclude testimony simply because the trial court does not deem the proposed expert to be the best qualified or because the proposed expert does not have the specialization that the court considers most appropriate." Holbrook, 80 F.3d at 782. If the expert meets liberal minimum qualifications, then the level of the expert's expertise goes to credibility and weight, not admissibility. See Paoli, 35 F.3d at 741. The Second Circuit addressed a similar issue and commented that the expert's alleged shortcomings were raised properly on cross-examination and went to the credibility, not the admissibility, of his testimony. McCullock v. H.B. Fuller Co., 61 F.3d 1038, 1043 (2d Cir.1995). Consequently, we reject Terminix's suggestion that Dr. Gerson must be a specialist in Dursban to provide expert testimony on the causation of Dr. Kannankeril's injury.
The Kannankerils' burden is only to provide an expert opinion that is relevant and reliable and that will assist the trier of fact. As we have repeated above, issues of credibility arise after the determination of admissibility. Credibility is for the jury. We conclude that, under the facts presented here, the district court erred in ruling that Dr. Gerson's expert testimony on causation was inadmissible.
IV. CONCLUSION
For the foregoing reasons, we hold that the district court erred as a matter of law in refusing to permit Dr. Gerson to testify as to his opinion of the causation of Dr. Kannankeril's illness. Accordingly, we will vacate that portion of the district court order which granted summary judgment against Dr. Mary Kannankeril, and we will remand this case for further proceedings consistent with this opinion.
Honorable Paul R. Michel, United States Court of Appeals for the Federal Circuit, sitting by designation
Our decision, vacating the summary judgment against Dr. Kannankeril, is without prejudice to any motion for summary judgment on other grounds which Terminix may bring
Only the causation of Dr. Kannankeril's cognitive impairment remains an issue in the case. These cognitive deficits include memory loss, concentration loss, sleeplessness, general anxiety, and headaches. Her other alleged physical symptoms included insomnia, numbness, muscle twitching, pain in muscles and joints, vaginal bleeding, urinary incontinence, nausea, skin rashes, and depigmentation patches throughout her body
Dr. Gerson's qualifications included: Physician certified by the American Board of Toxicology and the American Board of Pathology; Director of the Boston University School of Medicine's Laboratory of Analytical Toxicology and Director of the Research Data Worldwide Clinical Laboratory; Consultant to the Food and Drug Administration's Center for Devices and Radiological Health; Professor of Pathology and a Professor of Pharmacology & Experimental Therapeutics at Boston University; Instructor in Pathology, Harvard Medical School; Special Lecturer in Clinical Laboratory Science, Northeastern University; Assistant Professor of Pathology, Harvard Medical School; Associate Professor of Pathology, Harvard Medical School; Director of Clinical Chemistry and Toxicology at Veterans Affairs Medical Center in Boston, Massachusetts
Under New Jersey law, medical expert testimony must be made with a reasonable degree of certainty. See Bondi v. Pole, 246 N.J.Super. 236, 587 A.2d 285 (App.Div.1991); Vuocolo v. Diamond Shamrock Chemicals Co., 240 N.J.Super. 289, 573 A.2d 196 (1990); Johnesee v. The Stop & Shop Companies, 174 N.J.Super. 426, 416 A.2d 956 (App.Div.1980). New Jersey's rule should govern in the present case since it is a substantive law that is part of the appellants' burden of proof. See In re Paoli R.R. Yard PCB Litig., 35 F.3d 717, 752 (3d Cir.1994)
These nonexclusive guidelines, drawn from Daubert and this Court's opinion in United States v. Downing, 753 F.2d 1224 (3d Cir.1985), include:
(1) whether a method consists of a testable hypothesis; (2) whether the method has been subject to peer review; (3) the known or potential rate of error; (4) the existence and maintenance of standards controlling the technique's operation; (5) whether the method is generally accepted; (6) the relationship of the technique to methods which have been established to be reliable; (7) the qualifications of the expert witness testifying based on the methodology; and (8) the non-judicial uses to which the method has been put.
Paoli, 35 F.3d at 742 n. 8.
Terminix had, of course, no obligation to present an alternate theory of causation in its effort to have Dr. Gerson's opinion excluded. However, in determining whether a proper differential diagnosis was conducted, a consideration of other diagnoses may be relevant
In his opinion letter to plaintiffs' attorney, Dr. Gerson described chlorpyrifos, the active ingredient in Dursban, as an organophosphate insecticide, and he set out summaries of a number of reports of the delayed and chronic effects of exposure to organophosphates and of the effects on humans of organophosphate poisoning. A-47-51